What Happened to Outsourcing in Asia? - The industry may not be ready for India and China as regulatory issues emerge. - BioPharm International

ADVERTISEMENT

What Happened to Outsourcing in Asia?
The industry may not be ready for India and China as regulatory issues emerge.


BioPharm International
pp. 20-21

A DOSE OF REGULATORY REALITY
After several years of study data showing China and India becoming more heavily favored outsourcing destinations, this year's results are striking and merit some attention. There are some signs that respondents' increased attention to traditional hubs, at the expense of China and India, is likely related to a renewed focus on regulatory issues. This may be drawing industry attention away from emerging manufacturing clusters, where there may be less confidence in the regulatory expertise.

As with years past, geographic location continues to be one of the least important factors: only 7% of respondents this year indicated "be local to me" to be a "very important" consideration, squarely in the less than 2-10% range found in the past 4-5 years.

As geography plays a lesser role, regulatory expertise is becoming a crucial factor in decision-making. This year, 45.6% of respondents said that it was "very important" that CMOs have regulatory compliance expertise, a significant rise from 38.1% who attached that level of importance last year. This comes amidst separate data suggesting that biomanufacturers are focusing more on regulatory issues to improve operational performance and avoid capacity constraints. It could also be a result of clients outsourcing more core activities than in earlier years, with regulatory compliance more rigid for these activities than for the lower value-added services that have typified outsourcing in the past.

Finally, although much investment has been made in facilities in China and India for biogenerics production, some companies have been using their existing facilities, looking to leverage well-understood facilities that might otherwise be under utilized, and which are able to quickly and cheaply produce clinical material. Much of this CMO-sourced material has been produced in the US, which may be slanting future expectations for outsourcing.

LOOKING AHEAD
Although there has been a noticeable shift in attention away from China and India as outsourcing destinations, there is reason to believe this situation will reverse. Those countries are accounting for an ever-greater share of global biomanufacturing capacity—together, they represent approximately one-sixth of capacity, according to BioPlan's WIKI resource on global biopharmaceutical facilities (2), which pegs China's share of biopharmaceutical manufacturing concentration at 8.6% and India's at 8.1%. Although that's significantly behind North America (35.9%) and Western Europe (26.1%), it's a growing trend that the industry is not ignoring.

It's important to remember that China is a relatively new player, which continues to suffer from legal and regulatory aspects that hinder commercial-scale contract manufacturing. It may take years for Chinese CMOs to come up to full cGMP standards and to be permitted to operate at commercial scale. These study results may simply be a reflection of the industry thinking that such progress may not come as quickly as expected. Nevertheless, it's short-sighted to believe that this situation will not change. China and India represent a majority of the world's population, and with its growing middle class, biologics production will likely continue to play an important role in their healthcare policy. While some emerging destinations may not find substantial growth in the short term, India and China will need to produce biologics for their huge local populations, and some of this experience will have Western markets taking a close look at their capabilities.

Eric Langer is president of BioPlan Associates, tel. 301.921.5979,
.

REFERENCES

1. BioPlan Associates, 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (Rockville, MD, April 2013), http://www.bioplanassociates.com/10th

2. BioPlan Associate's Top 1000 Global Biopharmaceutical Facilities Index, http://www.top1000bio.com/, accessed May 27, 2013.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here